The most important measure of Bristol-Myers Squibb’s success as a next-generation BioPharma leader is the difference we make in the lives of patients. In addition, our ability to ensure the sustainability of our business is often measured by our sales growth.
The company's products are sold principally to the wholesale and retail trade. Certain products are also sold to other drug manufacturers, hospitals and the medical profession. Bristol-Myers Squibb is also committed to improving access to our medicines for patients who are unable to afford them.
Bristol-Myers Squibb's worldwide sales from continuing operations are shown in the following table:
Bristol-Myers Squibb products are available in virtually every country in the world. The company's largest markets include the United States, France, Canada, Japan, Italy, Spain, Germany, China and the United Kingdom.
|Rest of the World
*Other total revenues include royalties and other alliance-related revenues for products not sold by our regional commercial organizations.
In 2014, we invested $4.5 billion on pharmaceutical R&D, an amount that represents 28 percent of our pharmaceutical sales.
Bristol-Myers Squibb made provision for $352 million in income taxes in 2014. For more information on taxes paid, refer to the Notes to Consolidated Financial Statements of our Annual Report.